Bio-Rad Laboratories, Inc. (BIO)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2,546 | 2,923 | 2,802 | 2,671 | 2,567 | 2,583 | 2,589 | 2,584 |
| Operating profit | $m | 271 | 235 | ||||||
| Net profit | $m | 3,814 | 4,254 | -3,628 | -637 | -1,844 | 760 | 222 | 254 |
| EPS reported | $ | 27.87 | 8.25 | ||||||
| Operating cashflow per share | $ | 19.52 | 18.42 | ||||||
| Capex per share | $ | 5.78 | 5.22 | ||||||
| FCF per share | $ | 13.74 | 13.20 | ||||||
| Free cash flow | $m | 375 | 353 | ||||||
| Net debt | $m | -166 | -581 | ||||||
| Book value equity | $m | 7,454 | 7,174 | ||||||
| Book value per share | $ | 273.2 | 267.5 | ||||||
| Number of shares | m | 27.28 | 26.81 | ||||||
| DPS (TTM paid) | $ | 0.00 | 1.83 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 10.87 | 46.18 | ||||||
| P/B LTM | x | 1.11 | 1.15 | ||||||
| P/S LTM | x | 3.20 | 3.19 | ||||||
| P/FCF LTM | x | 22.05 | 23.39 | ||||||
| EV/EBITDA LTM | x | 7.41 | 17.32 | ||||||
| EV/Sales LTM | x | 3.58 | 4.28 | ||||||
| Earnings Yield LTM | % | +9.20% | +2.17% | ||||||
| FCF Yield | % | +4.53% | +4.27% | ||||||
| Quality | |||||||||
| ROE | % | +10.20% | +3.15% | ||||||
| ROIC | % | +2.04% | +1.54% | ||||||
| Operating margin | % | +10.47% | +9.08% | ||||||
| Gross margin | % | +52.01% | +51.90% | ||||||
| FCF/Sales | % | +14.50% | +13.64% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +0.65% | +0.89% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | +40.72% | +32.64% | ||||||
| Operating Profit Growth | % | +0.56% | -12.64% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | +22.06% | ||||||
| FCF/Debt | x | 0.24 | 0.29 | ||||||
| Net Debt/EBITDA | x | 0.80 | 1.28 | ||||||
| EBIT/Net interest | x | 5.52 | 6.40 | ||||||
| Net debt/market cap | % | +16.67% | +11.58% | ||||||
| Net debt/Equity | x | -0.02 | -0.08 | ||||||
| Gross debt/equity | x | 0.21 | 0.17 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free